| scholarly article | Q13442814 |
| P50 | author | Andrea Giuffrida | Q42429689 |
| Tommaso Cassano | Q42689344 | ||
| Maria Grazia Morgese | Q57080617 | ||
| P2093 | author name string | Vincenzo Cuomo | |
| P2860 | cites work | The capsaicin receptor: a heat-activated ion channel in the pain pathway | Q24322558 |
| Brain monoglyceride lipase participating in endocannabinoid inactivation | Q24533828 | ||
| Anandamide and vanilloid TRPV1 receptors | Q24672354 | ||
| The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin | Q24676808 | ||
| A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia | Q28569068 | ||
| Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain | Q28570094 | ||
| Modulation of anxiety through blockade of anandamide hydrolysis | Q29615902 | ||
| Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. | Q31039577 | ||
| Animal models of neurological deficits: how relevant is the rat? | Q31091605 | ||
| Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia | Q33255884 | ||
| The spectrum of levodopa-induced dyskinesias | Q33890225 | ||
| The endocannabinoid system as a target for therapeutic drugs. | Q33934278 | ||
| New perspectives on enigmatic vanilloid receptors. | Q34046213 | ||
| Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway | Q34133059 | ||
| Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 | ||
| Evidence for novel cannabinoid receptors | Q34415409 | ||
| Oxidative metabolism of endocannabinoids | Q34673106 | ||
| Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 | ||
| The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. | Q35626716 | ||
| Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time? | Q36352491 | ||
| Distribution of cannabinoid receptors in the central and peripheral nervous system. | Q36441196 | ||
| The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism | Q40817229 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function | Q42463405 | ||
| Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. | Q42492136 | ||
| Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain | Q42493166 | ||
| Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. | Q42501373 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease | Q42541635 | ||
| Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease | Q42695373 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Unawareness of dyskinesias in Parkinson's and Huntington's diseases | Q43696853 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide | Q44002298 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia | Q44344002 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors | Q44418969 | ||
| Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response | Q44434119 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias | Q45030408 | ||
| Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. | Q45173372 | ||
| Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. | Q45230637 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? | Q46591202 | ||
| Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications | Q46731448 | ||
| Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. | Q46859525 | ||
| Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine | Q46986296 | ||
| Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat. | Q48191276 | ||
| Quantification of endocannabinoids in rat biological samples by GC/MS: technical and theoretical considerations | Q48378533 | ||
| A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats | Q60690596 | ||
| Anandamide – the other side of the coin | Q60690621 | ||
| Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon | Q67588050 | ||
| The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway | Q70973782 | ||
| The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons | Q72302141 | ||
| Are cannabinoids endogenous ligands for the VR1 capsaicin receptor? | Q73423096 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| CNR2 | Q17907844 | ||
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| dyskinesia | Q629444 | ||
| P304 | page(s) | 110-119 | |
| P577 | publication date | 2007-08-22 | |
| P1433 | published in | Experimental Neurology | Q5421127 |
| P1476 | title | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors | |
| P478 | volume | 208 |
| Q35070472 | Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. |
| Q91860838 | Allostatic load and the cannabinoid system: implications for the treatment of physiological abnormalities in post-traumatic stress disorder (PTSD) |
| Q36034592 | Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum |
| Q42121362 | Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors |
| Q46518412 | Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. |
| Q30833645 | Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. |
| Q48407695 | Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry |
| Q42150000 | Cannabinoid Modulation of Memory Consolidation in Rats: Beyond the Role of Cannabinoid Receptor Subtype 1 |
| Q34680801 | Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. |
| Q46334332 | Cannabinoid rescue of striatal progenitor cells in chronic Borna disease viral encephalitis in rats |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
| Q91934280 | Cannabinoids and the expanded endocannabinoid system in neurological disorders |
| Q40701861 | Cannabinoids for the Treatment of Movement Disorders. |
| Q42258332 | Cannabinoids in Parkinson's Disease |
| Q48131059 | Capsaicin Protects Against Oxidative Insults and Alleviates Behavioral Deficits in Rats with 6-OHDA-Induced Parkinson's Disease via Activation of TRPV1. |
| Q30844366 | Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease |
| Q42028528 | Capsaicin-sensitive primary sensory neurons in the mouse express N-Acyl phosphatidylethanolamine phospholipase D. |
| Q35972575 | Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats |
| Q42095959 | Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism |
| Q38207680 | Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions |
| Q38182651 | Dyskinesias in Parkinson's disease: views from positron emission tomography studies |
| Q37396700 | Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease |
| Q38018946 | Endocannabinoid modulation of dopaminergic motor circuits. |
| Q35754490 | Endocannabinoid signalling and the deteriorating brain |
| Q38479031 | Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia |
| Q33751118 | In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability |
| Q45927862 | Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. |
| Q28298445 | International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ |
| Q37115808 | Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease |
| Q64781374 | Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? |
| Q37364829 | L-dopa therapy for Parkinson's disease: past, present, and future |
| Q37794467 | Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. |
| Q36422521 | Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q37924629 | Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. |
| Q38815779 | Microglial phenotypes in Parkinson's disease and animal models of the disease |
| Q37676906 | Multi-Functional Diarylurea Small Molecule Inhibitors of TRPV1 with Therapeutic Potential for Neuroinflammation |
| Q37132571 | Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 |
| Q42693744 | Neuroprotective Effects of β-Asarone Against 6-Hydroxy Dopamine-Induced Parkinsonism via JNK/Bcl-2/Beclin-1 Pathway |
| Q57165498 | New approaches and challenges to targeting the endocannabinoid system |
| Q36074595 | New insights on endocannabinoid transmission in psychomotor disorders |
| Q36776402 | New transient receptor potential vanilloid subfamily member 1 positron emission tomography radioligands: synthesis, radiolabeling, and preclinical evaluation. |
| Q41809772 | Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. |
| Q37208065 | Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q37644775 | Repetitive transcranial magnetic stimulation (rTMS) improves behavioral and biochemical deficits in levodopa-induced dyskinetic rats model |
| Q37525458 | Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity |
| Q48301223 | Synthesis and biological evaluation of [¹¹C]SB366791: a new PET-radioligand for in vivo imaging of the TRPV1 receptor. |
| Q91790432 | TRPV1 Tunes Optic Nerve Axon Excitability in Glaucoma |
| Q36824652 | TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. |
| Q37150745 | Targeting the endocannabinoid system: to enhance or reduce? |
| Q34482483 | The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats |
| Q42495608 | The bright side of psychoactive substances: cannabinoid-based drugs in motor diseases. |
| Q35740152 | The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
| Q57518128 | Therapy for dyskinesias in Parkinson’s disease patients |
| Q37371387 | WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. |
| Q39012371 | l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? |
| Q38951947 | l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements? |
Search more.